Trial of Qui Tam actions involving Amgen Inc. in Massachusetts will start on October 3, 2011, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended June 30, 2011.
A…
Reynolds American Inc. is awaiting a court decision on its and other plaintiffs’ motion for preliminary injunction in a lawsuit brought against the city of Worcester, Massachusetts, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S.…
H&R Block, Inc., entered into a settlement agreement to resolve the lawsuit commenced by the Massachusetts Attorney General alleging unfair, deceptive and discriminatory origination and servicing of mortgage loans, the Company disclosed in its September 1, 2011, Form 10-Q filing…
Forest Laboratories Inc. continues to cooperate in an investigation of the U.S. Attorney’s Office for the District of Massachusetts related to its commercial relationship with Omnicare, Inc. (Omnicare), a long-term care pharmacy provider, the company disclosed in its latest annual…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with U.S. Attorney s Office for the District of Massachusetts.
In March 2009, Merck received a…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with U.S. Attorney s Office for the District of Massachusetts.
In March 2009, Merck received a…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it anticipates the trial on the Massachusetts Department of Revenue’s US$38.9 million tax assessment against its wholly owned subsidiary,…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the European Commission, or the EC, published its final report on an inquiry in July 2009 in which it…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that on June 15, 2009, a panel issued its final decision in the arbitration filed by the Company against Genentech,Inc.…
Mediation on outstanding claims filed against Biogen Idec Inc. and its subsidiary Biogen Inc. (n/k/a Biogen Idec MA Inc.) over certain drugs for which Medicaid provides reimbursement (covered drugs) is still ongoing, The Company disclosed in its latest quarterly report…